uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 08:40PM GMT
Release Date Price: $37.52
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and I'm pleased to welcome uniQure. And with us we have Matt Kapusta, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Matt, thank you for joining us. And to start here, maybe we could talk about the overall strategy for the company here. You've out-licensed the development and commercialization of your lead product or your lead gene therapy product, Phase III EtranaDez in hemophilia B, to CSL Behring. And could you just remind us as to your forward strategy for the overall portfolio, though, focus on neurology and liver disease? And how you're even thinking about BD in that context?

Matthew Craig Kapusta
uniQure N.V. - CEO, CFO & Executive Director

Yes. Sure. Well, thanks for having us, Salveen. Yes, so uniQure's mission still is to be a fully integrated gene therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot